3.96
-0.02(-0.50%)
Currency In USD
| Previous Close | 3.98 |
| Open | 3.98 |
| Day High | 4.05 |
| Day Low | 3.92 |
| 52-Week High | 26.62 |
| 52-Week Low | 2.88 |
| Volume | 141,631 |
| Average Volume | 235,993 |
| Market Cap | 141.97M |
| PE | -2 |
| EPS | -1.98 |
| Moving Average 50 Days | 3.93 |
| Moving Average 200 Days | 9.49 |
| Change | -0.02 |
If you invested $1000 in BioAge Labs, Inc. (BIOA) since IPO date, it would be worth $216.28 as of June 02, 2025 at a share price of $3.96. Whereas If you bought $1000 worth of BioAge Labs, Inc. (BIOA) shares 6 months ago, it would be worth $226.93 as of June 02, 2025 at a share price of $3.96.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic
GlobeNewswire Inc.
May 29, 2025 1:00 PM GMT
IND submission planned for mid-2025 with Phase 1 SAD data anticipated by year end BGE-102 induced weight loss in preclinical obesity models, both as monotherapy and in combination with GLP-1 receptor agonistsInternally discovered compound has a novel
BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference
GlobeNewswire Inc.
Feb 20, 2025 9:30 PM GMT
RICHMOND, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human
BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs
GlobeNewswire Inc.
Jan 28, 2025 2:00 PM GMT
Advancement of next-generation APJ agonists with discontinuation of azelaprag Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial Ph1 clinical data anticipated by end of 2025 Expansion of discovery efforts based on insights